Rhythm Pharmaceuticals, Inc. (RYTM): Net Income
-$196.54M
Year ended 2025-12-31
-$205.35M
Trailing 12 months to 2026-06-30
| Period ended | Net Income | Change YoY | Source filing |
|---|---|---|---|
| 2025-12-31 | -$196.54M | n/m | 2026-02-26, From 2025-01-01 |
| 2024-12-31 | -$260.60M | n/m | 2026-02-26, From 2024-01-01 |
| 2023-12-31 | -$184.68M | n/m | 2026-02-26, From 2023-01-01 |
| 2022-12-31 | -$181.12M | n/m | 2025-02-28, From 2022-01-01 |
| 2021-12-31 | -$69.61M | n/m | 2024-02-29, From 2021-01-01 |
| 2020-12-31 | -$134.00M | n/m | 2023-03-01, From 2020-01-01 |
| 2019-12-31 | -$140.73M | n/m | 2021-03-01, From 2019-01-01 |
| 2018-12-31 | -$74.06M | n/m | 2021-03-01, From 2018-01-01 |
| 2017-12-31 | -$33.71M | n/m | 2020-03-02, From 2017-01-01 |
| 2016-12-31 | -$25.87M | n/m | 2019-03-08, From 2016-01-01 |
| 2015-12-31 | -$11.07M | n/a | 2018-03-12, From 2015-01-01 |
Net Income at similar companies
| Company | Year ended | Net Income | Change YoY |
|---|---|---|---|
| Rhythm Pharmaceuticals, Inc. (RYTM) | 2025-12-31 | -$196.54M | n/m |
| Maravai Lifesciences Holdings, Inc. (MRVI) | 2025-12-31 | -$130.77M | n/m |
| Stoke Therapeutics, Inc. (STOK) | 2025-12-31 | -$6.88M | n/m |
| Lifevantage Corp (LFVN) | 2026-06-30 | $5.07M | -48.3% |
| Cryoport, Inc. (CYRX) | 2025-12-31 | $78.30M | n/m |
| Phathom Pharmaceuticals, Inc. (PHAT) | 2025-12-31 | -$221.25M | n/m |
| Syndax Pharmaceuticals Inc (SNDX) | 2025-12-31 | -$285.42M | n/m |
| Amarin Corp PLC (AMRN) | 2025-12-31 | -$38.80M | n/m |
| Vanda Pharmaceuticals Inc. (VNDA) | 2025-12-31 | -$220.47M | n/m |
Compare RYTM, MRVI, STOK, LFVN side by side · Screen every company in Pharmaceutical Preparations ↗